| CAS | 910463-68-2 |
| Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Sequence Single | H-Aib-EGTFTSDVSSYLEGQAAK(AEEAc-AEEAc-γ-E-17-carboxyheptadecanoyl)-EFIAWLVRGRG |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.64 |
| Synonyms | NN9535 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Diabetes |
| Description | Semaglutide also called NN9535, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment. |
| References | 1. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. B.B.Holmes et al., Proc. Natl. Acad. Sci. USA, 110, E3138 (2013) 2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. 3. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model. Zhang L, et al. Neuropeptides. 2018 Oct;71:70-80. 4. Semaglutide: First Global Approval. Dhillon S, et al. Drugs. 2018 Feb;78(2):275-284. |